Isotonic designs for phase I cancer clinical trials with multiple risk groups

Clinical Trials

Volumn 1, Issue 6, 2004, Pages 499-508

  Yuan, Zhilong ^a   Chappellb, Rick ^b  

^a University of Wisconsin   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BIOLOGICAL MODEL; DRUG TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEOPLASM; PHASE 1 CLINICAL TRIAL; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 33644632237     PISSN: 17407745     EISSN: None     Source Type: Journal    
DOI: 10.1191/1740774504cn058oa     Document Type: Article

References (19)

1. Rosenberger W.F., Haines L.M. Competing designs of phase I clinical trials. Stat Med 2002; 21: 2757-2770.
2. Mehta M., Scrimger R., Mackie R., Paliwal B., Chappell R., Fowler J. A new approach to dose escalation in non-small cell lung cancer. Int J Rad Oncol Biol Phys 2001; 49: 23-33.
3. Piantadosi S., Liu G. Improved designs for dose escaltion studies using pharmacokinetic measurements. Stat Med 1996; 15: 1605-1618.
4. Chevret S. The continual reassessment method in cancer phase I cancer clinical trials: a simulation study. Stat Med 1993; 12: 1093-1108.
5. Goodman S., Zahurak M., Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-1161.
6. Storer B.E. Design and analysis of Phase I clinical trials. Biometrics 1989; 45: 925-937.
7. Leung D.H.Y., Wang Y.G. Isotonic designs for phase I trials. Control Clin Trials 2001; 22: 126-138.
8. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
9. O'Quigley J., Shen L.Z. Continual reassessment method: a likelihood approach. Biometrics 1991; 52: 673-684.
10. Babb S., Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Stat Med 2001; 20: 2079-2090.
11. Wijesinha M.C., Piantadosi S. Dose-response models with covariates. Biometrics 1995; 51: 977-987.
12. Ratain M.J., Rosemarie M., Janisch L. et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996; 6: 93-101.
13. Legedza A.T.R., Ibrahim J.G. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. Stat Med 2001; 20: 867-882.
14. Cheng J., Babb J.S., Langer C. et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol 2004; 2: 602-609.
15. Babb J., Rogatko A., Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998; 17: 1103-1120.
16. O'Quigley J., Shen L.Z., Gamst A. Two-sample continual reassessment method. J Biopharm Stat 1999; 9: 17-44.
17. O'Quigley J., Paoletti X. Continual reassessment method for ordered groups. Biometrics 2003; 59: 430-440.
18. Robertson T., Wright F.T., Dykstra R.L. Order restricted statistical inference. New York: John-Wiley and Sons, 1988.
19. O'Quigley J., Chevret S. Methods for dose finding studies in cancer clinical trials: a review of results of a monte carlo study. Stat Med 1991; 10: 1647-1664.